R. Andrew Harkins, MD, MS

Peer-Reviewed Articles

1. Chihara D, Balakrishnan K, Masand G, Harkins RA, Akkad N, Alekseeva E, Nesmelov A, Shugaev-Mendosa E, Anosov I, Rusinov A, Postovalova E, Gracheva Y, Lauziere K, Paradiso F, Kotlov N, Bagaev A, Green MR, Fowler NH, Flowers CR, Westin JR. Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma. Blood Adv, 2026. e-Pub 2026. PMID: 42498283.
2. Xie C, Chihara D, Harkins RA, Li R, Flowers CR. Integrating Information Across Datasets to Improve Prognostic Models for Patients with Diffuse Large B-cell Lymphoma. e-Pub 2026.
3. Li X, Singhal K, Deng Q, Chihara D, Russler-Germain D, Harkins RA, Henderson J, Arita K, Kizhakeyil A, Sun R, Lakra P, Hussein U, Foltz JA, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Kesaraju A, Hamilton MP, Allen C, Gandhi MK, Tobin J, Jiang A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. Large B-Cell Lymphoma Microenvironment Archetype Profiles. Cancer Cell, 2025. e-Pub 2025. PMID: 40920660.
4. Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum K, Cashen AF, Casulo C, Friedberg JW, Johnston P, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan P, Westin JR, Koff JL, Flowers CR. Improving Eligibility Criteria for First-Line Trials for Patients with DLBCL Using a U.S.-Based Delphi-Method Survey. Blood Adv, 2022. e-Pub 2022. PMID: 35100356.
5. Lee MJ, Koff JL, Switchenko JM, Jhaney CI, Harkins RA, Patel SP, Dave S, Flowers CR. Genome-Defined African Ancestry is Associated with Distinct Mutations and Worse Survival in Diffuse Large B-Cell Lymphoma. Cancer, 2020. e-Pub 2020. PMID: 32469082.
6. Patel SP, Harkins RA, Lee MJ, Flowers CR, Koff JL. Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk, 2019. e-Pub 2019. PMID: 32063526.
7. Harkins RA, Edelman SE, Singh P, Hernandez M, Ayers AA, Noorani M, Zuniga T, Valceral B, Chihara D, Furgan F, Ahmed S, Iyer S, Neelalpu S, Fayad L, Hagameister FB, Nze C, Jain P, Wang M, Strati P, Chauhan A, Vega F, Flowers CR, Westin JR. Retreatment with R-CHOP-like therapy is active with durable response in patients with late relapse diffuse large B-cell lymphoma. Blood Adv.
8. Arita K, Dai E, Li X, Sheikh IN, Reville PK, Henderson JM, Wilson A, Dillard C, Bowman K, Yang H, Chu F, Harkins RA, Pate N, Malley K, Bangari D, Rojas E, Westin JR, Ahmed S, Neelapu SS, Vega F, Wang R, Li X, Shaffer D, Wang L, Green MR. CD8 T cell dysfunction linked with CAR T cell failure can be mitigated by a non-alpha IL2 receptor agonist, pegenzileukin.
9. Harkins RA, Harris W, Green MR, Li X, Herrera A, Jardin F, Lenz G, Morschhauser F, Sufidono M, Yan M, Batlevi CL, Flowers CR, Jiang Y. Outcomes by LymphoMAP archeotypes in untreated diffuse large B-cell lymphoma from the POLARIX trial.

Invited Articles

1. Harkins RA, Flowers CR. How Should Clinicians Interpret Conflicting Cost-Effectiveness Analyses for the Treatment of Lymphoma Across Nations and Payer Models?. Leuk Lymphoma, 2020. e-Pub 2020. PMID: 33143518.

Review Articles

1. Lee MJ, Abousaud A, Harkins RA, Marin E, Balasubramani D, Churnetski MC, Peker D, Singh A, Koff JL. Important Considerations in the Diagnosis and Management of Post-Transplant Lymphoproliferative Disorder. Curr Oncol Rep, 2023. e-Pub 2023. PMID: 37162742.
2. Harkins RA, Patel SP, Flowers CR. Cost-Effectiveness of New Targeted Agents in Chronic Lymphocytic Leukemia. Cancer J, 2019. e-Pub 2019. PMID: 31764123.
3. Harkins RA, Patel SP, Flowers CR. Cost Burden of Diffuse Large B-Cell Lymphoma. Expert Rev Pharmacoecon Outcome Res, 2019. e-Pub 2019. PMID: 31623476.
4. Harkins RA, Chang A, Patel SP, Lee MJ, Goldstein J, Merdan S, Flowers CR, Koff JL. Remaining Challenges in Predicting Patient Outcomes for Diffuse Large B-Cell Lymphoma. Expert Rev Hematol, 2019. e-Pub 2019. PMID: 31513757.

Abstracts

1. Patel SP, Harkins RA, Lee MJ, Flowers CR. Using Informatics Tools to Characterize Precision Medicine Treatments for Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology Annual Meeting and Exposition.
2. Harkins RA, Flowers CR. Defining Parsimonious Eligibility Criteria in Precision Medicine Clinical Trials for Diffuse Large B-Cell Lymphoma. Association for Clinical and Translational Science (ACTS) Translational Science Conference.
3. Harkins RA, Patel SP, Lee MJ, Switchenko JM, Flowers CR. A Data-Driven Approach to Define Parsimonious Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma. American Society of Hematology Annual Meeting and Exposition.
4. Harkins RA, Tejani MN, Henry TL, George MR. High-Risk Counties in Rural Georgia Where Cancer Treatment is Likely to be Affected by Proposed Cuts to the 340B Drug Pricing Program. 10th Annual Emory University School of Medicine Social Medicine Forum.
5. Coleman CG, Massie AM, Harkins RA, Wigger GW, Daniels LM. Double Trouble with Olanzapine Overdose. American Thoracic Society International Conference.
6. Lee MJ, Koff JL, Hildebrandt MAT, Switchenko JM, Jhaney CI, Harkins RA, Patel SP, Dave SS, Flowers CR. Mutational Landscape of Diffuse Large B-Cell Lymphoma in Patients with Genome-Defined African Ancestry. 13th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.
7. Harkins RA, Flowers CR. Modernizing Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma: Consensus Recommendations Using a Modified Delphi-Method Survey. American Society of Hematology Annual Meeting and Exposition.
8. Harkins RA, Rollin FG. Acute Parotitis Associated with COVID-19: A Case Report. 18th Annual Department of Medicine Resident Research Day.
9. Harkins RA, Chihara D, Flowers CR. Collective Analysis of Genomic Data Sets to Assess the Impact of Eligibility Criteria on Molecular Subsets in First-Line Clinical Trials for Patients with Diffuse Large B-Cell Lymphoma. American Society of Hematology Annual Meeting and Exposition.
10. Chihara D, Balakrishnan K, Masand G, Harkins RA, Akkad N, Novokreshchenova A, Bagaev A, Kotlov N, Postovalova E, Shugaev-Mendosa E, Gracheva Y, Lauziere K, Kaneunyenye L, McKenna B, Berlinski A, Walsh M, Larson L, Kotsinyan M, Samokhina A, Yong S, Nomie K, Fowler N, Flowers CR, Westin J. Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma. American Society of Hematology Annual Meeting and Exposition.
11. Harkins RA, Harris W, Green MR, Herrera A, Jardin F, Lenz G, Morschhauser F, Sugidono M, Yan M, Batlevi CL, Flower CR, Jiang Y. Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial. American Society of Clinical Oncology.
12. Harkins RA, Harris W, Green MR, Herrera A, Jardin F, Lenz G, Morschhauser F, Sugidono M, Yan M, Batlevi CL, Flowers CR, Jiang Y. Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial. European Hematology Association.
13. Abe Y, Thakkar B, Kizhakeyil A, Wilson A, Feldman A, Henderson J, Ayers A, Borgschatz S, Harkins RA, Lakra P, Cohen J, Kahl B, Mou E, Vega F, Chapman J, Inhirami G, Friedberg J, Lossos I, Koff J, Nze C, Martin P, Syrbu S, Vij K, Jaye D, Cerhan J, Flowers CR, Novak A, Burack R, Chihara D, Sakata-Yanagimoto M, Tobin J, Li X, Green, MR. Spatially resolved microenvironment profiling reveals distinct follicular lymphoma archetypes. AACR Advances in Malignant Lymphoma: From Discovery to Clinical Impact.
14. Arita K, Dai E, Li X, Sheikh IN, Reville P, Henderson J, Wilson A, Dillard C, Bowman K, Yang H, Chu F, Harkins, RA, Pate N, Malley K, Bangari D, Rojas E, Westin JR, Ahmed S, Neelapu SS, Vega F, Wang R, Li X, Shaffer D, Wang L, Green MR. Non-alpha IL2R agonist improves CAR T-cell therapy by preventing CAR T dysfunction in relapsed/refractory large B-cell lymphoma. AACR Advances in Malignant Lymphoma: From Discovery to Clinical Impact.